Robert Lustig on Fasting Insulin and Glucose Monitoring: recommends

Dr. Robert Lustig recommends tracking fasting insulin, which he describes as the most underrated metabolic biomarker, and says continuous glucose monitoring can reveal metabolic dysfunction before standard labs do. He is an advisor to Levels, a glucose-monitoring company.

His stated reasoning is that metabolic dysfunction begins long before it shows up in conventional bloodwork: insulin dynamics, he argues, are the upstream driver of chronic disease, so measuring insulin and glucose directly gives earlier signal than standard panels. As with any biomarker claim, this is Lustig’s stated position, not medical advice.

This page chronicles a stated position of the person above. It is not medical advice and not the site's own conclusion.